117 related articles for article (PubMed ID: 29276047)
1. Overcoming Resistance to the THZ Series of Covalent Transcriptional CDK Inhibitors.
Gao Y; Zhang T; Terai H; Ficarro SB; Kwiatkowski N; Hao MF; Sharma B; Christensen CL; Chipumuro E; Wong KK; Marto JA; Hammerman PS; Gray NS; George RE
Cell Chem Biol; 2018 Feb; 25(2):135-142.e5. PubMed ID: 29276047
[TBL] [Abstract][Full Text] [Related]
2. EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma.
Iniguez AB; Stolte B; Wang EJ; Conway AS; Alexe G; Dharia NV; Kwiatkowski N; Zhang T; Abraham BJ; Mora J; Kalev P; Leggett A; Chowdhury D; Benes CH; Young RA; Gray NS; Stegmaier K
Cancer Cell; 2018 Feb; 33(2):202-216.e6. PubMed ID: 29358035
[TBL] [Abstract][Full Text] [Related]
3. KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS.
Ambrogio C; Köhler J; Zhou ZW; Wang H; Paranal R; Li J; Capelletti M; Caffarra C; Li S; Lv Q; Gondi S; Hunter JC; Lu J; Chiarle R; Santamaría D; Westover KD; Jänne PA
Cell; 2018 Feb; 172(4):857-868.e15. PubMed ID: 29336889
[TBL] [Abstract][Full Text] [Related]
4. ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment.
Patel H; Periyasamy M; Sava GP; Bondke A; Slafer BW; Kroll SHB; Barbazanges M; Starkey R; Ottaviani S; Harrod A; Aboagye EO; Buluwela L; Fuchter MJ; Barrett AGM; Coombes RC; Ali S
Mol Cancer Ther; 2018 Jun; 17(6):1156-1166. PubMed ID: 29545334
[TBL] [Abstract][Full Text] [Related]
5. High MITF Expression Is Associated with Super-Enhancers and Suppressed by CDK7 Inhibition in Melanoma.
Eliades P; Abraham BJ; Ji Z; Miller DM; Christensen CL; Kwiatkowski N; Kumar R; Njauw CN; Taylor M; Miao B; Zhang T; Wong KK; Gray NS; Young RA; Tsao H
J Invest Dermatol; 2018 Jul; 138(7):1582-1590. PubMed ID: 29408204
[TBL] [Abstract][Full Text] [Related]
6. Enhancer invasion shapes MYCN-dependent transcriptional amplification in neuroblastoma.
Zeid R; Lawlor MA; Poon E; Reyes JM; Fulciniti M; Lopez MA; Scott TG; Nabet B; Erb MA; Winter GE; Jacobson Z; Polaski DR; Karlin KL; Hirsch RA; Munshi NP; Westbrook TF; Chesler L; Lin CY; Bradner JE
Nat Genet; 2018 Apr; 50(4):515-523. PubMed ID: 29379199
[TBL] [Abstract][Full Text] [Related]
7. Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13.
Zeng M; Kwiatkowski NP; Zhang T; Nabet B; Xu M; Liang Y; Quan C; Wang J; Hao M; Palakurthi S; Zhou S; Zeng Q; Kirschmeier PT; Meghani K; Leggett AL; Qi J; Shapiro GI; Liu JF; Matulonis UA; Lin CY; Konstantinopoulos PA; Gray NS
Elife; 2018 Nov; 7():. PubMed ID: 30422115
[TBL] [Abstract][Full Text] [Related]
8. Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer.
Wu YM; Cieślik M; Lonigro RJ; Vats P; Reimers MA; Cao X; Ning Y; Wang L; Kunju LP; de Sarkar N; Heath EI; Chou J; Feng FY; Nelson PS; de Bono JS; Zou W; Montgomery B; Alva A; ; Robinson DR; Chinnaiyan AM
Cell; 2018 Jun; 173(7):1770-1782.e14. PubMed ID: 29906450
[TBL] [Abstract][Full Text] [Related]
9. Cdk9 regulates a promoter-proximal checkpoint to modulate RNA polymerase II elongation rate in fission yeast.
Booth GT; Parua PK; Sansó M; Fisher RP; Lis JT
Nat Commun; 2018 Feb; 9(1):543. PubMed ID: 29416031
[TBL] [Abstract][Full Text] [Related]
10. SRPKIN-1: A Covalent SRPK1/2 Inhibitor that Potently Converts VEGF from Pro-angiogenic to Anti-angiogenic Isoform.
Hatcher JM; Wu G; Zeng C; Zhu J; Meng F; Patel S; Wang W; Ficarro SB; Leggett AL; Powell CE; Marto JA; Zhang K; Ki Ngo JC; Fu XD; Zhang T; Gray NS
Cell Chem Biol; 2018 Apr; 25(4):460-470.e6. PubMed ID: 29478907
[TBL] [Abstract][Full Text] [Related]
11. CDK12: an emerging therapeutic target for cancer.
Lui GYL; Grandori C; Kemp CJ
J Clin Pathol; 2018 Nov; 71(11):957-962. PubMed ID: 30104286
[TBL] [Abstract][Full Text] [Related]
12. Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing.
Viswanathan SR; Ha G; Hoff AM; Wala JA; Carrot-Zhang J; Whelan CW; Haradhvala NJ; Freeman SS; Reed SC; Rhoades J; Polak P; Cipicchio M; Wankowicz SA; Wong A; Kamath T; Zhang Z; Gydush GJ; Rotem D; ; Love JC; Getz G; Gabriel S; Zhang CZ; Dehm SM; Nelson PS; Van Allen EM; Choudhury AD; Adalsteinsson VA; Beroukhim R; Taplin ME; Meyerson M
Cell; 2018 Jul; 174(2):433-447.e19. PubMed ID: 29909985
[TBL] [Abstract][Full Text] [Related]
13. Discovery of 3-Benzyl-1-( trans-4-((5-cyanopyridin-2-yl)amino)cyclohexyl)-1-arylurea Derivatives as Novel and Selective Cyclin-Dependent Kinase 12 (CDK12) Inhibitors.
Ito M; Tanaka T; Toita A; Uchiyama N; Kokubo H; Morishita N; Klein MG; Zou H; Murakami M; Kondo M; Sameshima T; Araki S; Endo S; Kawamoto T; Morin GB; Aparicio SA; Nakanishi A; Maezaki H; Imaeda Y
J Med Chem; 2018 Sep; 61(17):7710-7728. PubMed ID: 30067358
[TBL] [Abstract][Full Text] [Related]
14. Identification of the genetic and clinical characteristics of neuroblastomas using genome-wide analysis.
Uryu K; Nishimura R; Kataoka K; Sato Y; Nakazawa A; Suzuki H; Yoshida K; Seki M; Hiwatari M; Isobe T; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Koh K; Hanada R; Oka A; Hayashi Y; Ohira M; Kamijo T; Nagase H; Takimoto T; Tajiri T; Nakagawara A; Ogawa S; Takita J
Oncotarget; 2017 Dec; 8(64):107513-107529. PubMed ID: 29296183
[TBL] [Abstract][Full Text] [Related]
15. Early and late effects of pharmacological ALK inhibition on the neuroblastoma transcriptome.
Claeys S; Denecker G; Cannoodt R; Kumps C; Durinck K; Speleman F; De Preter K
Oncotarget; 2017 Dec; 8(63):106820-106832. PubMed ID: 29290991
[TBL] [Abstract][Full Text] [Related]
16. Homolog-Selective Degradation as a Strategy to Probe the Function of CDK6 in AML.
Brand M; Jiang B; Bauer S; Donovan KA; Liang Y; Wang ES; Nowak RP; Yuan JC; Zhang T; Kwiatkowski N; Müller AC; Fischer ES; Gray NS; Winter GE
Cell Chem Biol; 2019 Feb; 26(2):300-306.e9. PubMed ID: 30595531
[TBL] [Abstract][Full Text] [Related]
17. Cyclin-Dependent Kinase 12, Immunity, and Prostate Cancer.
Antonarakis ES
N Engl J Med; 2018 Sep; 379(11):1087-1089. PubMed ID: 30207914
[No Abstract] [Full Text] [Related]
18. Platinum sensitivity and DNA repair in a recently established panel of patient-derived ovarian carcinoma xenografts.
Guffanti F; Fratelli M; Ganzinelli M; Bolis M; Ricci F; Bizzaro F; Chilà R; Sina FP; Fruscio R; Lupia M; Cavallaro U; Cappelletti MR; Generali D; Giavazzi R; Damia G
Oncotarget; 2018 May; 9(37):24707-24717. PubMed ID: 29872499
[TBL] [Abstract][Full Text] [Related]
19. Cyclin K regulates prereplicative complex assembly to promote mammalian cell proliferation.
Lei T; Zhang P; Zhang X; Xiao X; Zhang J; Qiu T; Dai Q; Zhang Y; Min L; Li Q; Yin R; Ding P; Li N; Qu Y; Mu D; Qin J; Zhu X; Xiao ZX; Li Q
Nat Commun; 2018 May; 9(1):1876. PubMed ID: 29760377
[TBL] [Abstract][Full Text] [Related]
20. Collapsing the Tumor Ecosystem: Preventing Adaptive Response to Treatment by Inhibiting Transcription.
Carugo A; Draetta GF
Cancer Discov; 2018 Jan; 8(1):17-19. PubMed ID: 29311224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
